CloneID: MLTA3698A (Pateclizumab)
Antigen Long Description: This humanized antibody was derived from a mouse anti-human LT-α hybridoma mAb.
Buffer Composition: PBS only.
Uniprot Accession No.: P01374
Specificity Statement: This antibody is specific for lymphotoxin-alpha, and is able to bind both the soluble LTα3 homotrimeric form and the cell-surface LTα1β2 heterotrimer, which is transiently expressed on activated B and T cells (Th1, Th17).
Application Notes (Clone): This antibody has been shown to able to both block LTα-mediated signaling and selectively deplete LTα-expressing activated T and B cells, which has therapeutic applications in abrogating proinflammatory responses in rheumatoid arthritis (RA) pathology (Kennedy, 2014). Preliminary clinical trials demonstrated that administration of this antibody decreased serum levels of CXCL13, a biomarker of RA disease activity (Emu, 2012). In a phase II trial, this antibody had a trend for clinical effects on the symptoms of RA after 3 months of treatment, but the differences from placebo responses were not statistically significant (Kennedy, 2014). In a human peripheral blood mononuclear cell transplanted SCID mouse model of graft-versus-host disease, this antibody specifically depleted activated LTα-expressing human donor T and B cells, prolonging survival of the mice (Chiang, 2012). Finally, this antibody has been used to in FC and surface plasmon resonance analysis to characterise its interaction with the LTα ligand.
English
Deutsch
